ACCC’s 2017 survey: cost of treatment is top threat to cancer program growth

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Amidst a dramatically changing healthcare landscape and increasingly competitive market, the Association of Community Cancer Centers eighth annual Trending Now in Cancer Care survey, which was conducted in partnership with Advisory Board’s Oncology Roundtable, identifies current and emerging trends across U.S. cancer programs.

When asked to identify the top threats to future cancer program growth, 68 percent of respondents selected cost of drugs and/or new treatment modalities as the number one threat, 47 percent named physician alignment around services and program goals, and 46 percent cited changes in healthcare coverage.

Respondents also identified cuts to fee-for-service reimbursement and the move to value-based care as significant threats to cancer program growth. One in three reported marketplace competition as a top threat. More than 290 respondents from 209 organizations participated in the 2017 survey.

Asked to identify their greatest opportunities for cost savings, respondents overwhelmingly pointed toward clinical standardization (63%) and drugs (62%). Providers see clinical standardization as a way to help reduce variation in care and eliminate duplicative services, thereby realizing cost savings.

Nearly 30 percent of respondents intend to improve clinical standardization by adopting clinical pathways for medical oncology, either vendor sponsored or homegrown. One in four survey respondents expect to realize cost savings by reducing capital expenses, such as radiation and imaging equipment.

The ACCC Trending Now in Cancer Care survey provides insights into nationwide developments in the business of cancer care. With today’s cancer patients acting more like consumers with a say in where they receive care, cancer programs continue to grow their service lines to meet this demand for personalized, patient-centered care, specifically around symptom management and survivorship.

The survey results also reveal trends around market consolidation and the rise in marketplace partnerships, participation in value-based contracts, and barriers to meeting accreditation and quality reporting requirements.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login